READ-ONLY DIGITIZATION RESULT
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.
J Clin Oncol · 2025-May · PMID 39879577
Panel Deterioration_Free_of_patients_提取完成待 EXE 对齐验证
time to deterioration
FIG 3. TTD in patient-reported lung cancer symptoms. TTD in the EORTC QLQ-LC13 composite lung cancer symptom score (cough, dyspnea, and chest pain). A clinically meaningful change was defined as an 11.1-point (for dyspnea) or 33.3-point (for cough or chest pain) deterioration for the EORTC QLQ-LC13 composite score scale. EORTC, European Organization for Research and Treatment of Cancer; HR, hazard ratio; NE, not estimable; QLQ-LC13, quality-of-life questionnaire-lung cancer 13; TTD, time to deterioration.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-18T20:17:49+00:00 |